• Explore /
  • Poster
  • / Interim results from a phase Ib/II clinical study of the glutaminase inhibitor telaglenastat (CB-839) in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS).

Interim results from a phase Ib/II clinical study of the glutaminase inhibitor telaglenastat (CB-839) in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS).

Abstract Poster

Authors

null

Veronica Guerra

MD Anderson Hematology/Oncology Fellowship, Houston, TX

Veronica Guerra , Courtney Denton Dinardo , Marina Konopleva , Jan Andreas Burger , Gautam Borthakur , Elias Jabbour , Naveen Pemmaraju , Kimberley Sheppard , Guillermo Garcia-Manero , Hagop M. Kantarjian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT03047993

Citation

J Clin Oncol 37, 2019 (suppl; abstr 7037)

DOI

10.1200/JCO.2019.37.15_suppl.7037

Abstract #

7037

Poster Bd #

412

Abstract Disclosures

Similar Posters

First Author: Kristen McCullough

First Author: Ehab L. Atallah

First Author: Funda Meric-Bernstam

Poster

2018 ASCO Annual Meeting

Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).

Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).

First Author: Anna F. Farago